Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 5 · 71.4%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Mortality (all‐cause) · patients with chronic obstructive pulmonary disease

It is very uncertain whether once‐daily ICS/LABA combined inhalers changes mortality (all‐cause) compared with once‐daily LAMA (very low certainty).

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
OR 0.2 [0.02, 1.73]
2 studies · 880 participants
Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both · patients with chronic obstructive pulmonary disease

It is very uncertain whether once‐daily ICS/LABA combined inhalers changes any COPD exacerbation that requires short‐burst oral corticosteroids… compared with once‐daily LAMA (very low certainty).

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
OR 0.72 [0.35, 1.5]
2 studies · 880 participants
Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Pneumonia · patients with chronic obstructive pulmonary disease

It is very uncertain whether once‐daily ICS/LABA combined inhalers changes pneumonia compared with once‐daily LAMA (very low certainty).

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
OR 6.12 [0.73, 51.24]
2 studies · 880 participants
Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Quality of life · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 779 participants
Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Hospital admissions · patients with chronic obstructive pulmonary disease

It is very uncertain whether once‐daily ICS/LABA combined inhalers changes hospital admissions (all‐cause) compared with once‐daily LAMA (very low certainty).

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
OR 0.96 [0.49, 1.89]
2 studies · 880 participants
Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Exacerbations leading to intubation · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Physical activity measure (e.g. 6MWT) · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found